In a report released yesterday, Chris Shibutani from Goldman Sachs maintained a Buy rating on Royalty Pharma (RPRX – Research Report). The company’s shares closed yesterday at $29.56.
According to TipRanks, Shibutani is a 5-star analyst with an average return of 20.6% and a 44.70% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Exelixis, BioNTech SE, and Neurocrine.
Royalty Pharma has an analyst consensus of Strong Buy, with a price target consensus of $44.67, representing a 51.12% upside. In a report released on August 9, Morgan Stanley also maintained a Buy rating on the stock with a $53.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Royalty Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $501.35 million and a net profit of $227.63 million. In comparison, last year the company earned a revenue of $515.35 million and had a net profit of $304.5 million
Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
New York-based Royalty Pharma Plc is a biopharmaceutical company, which is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry.
Read More on RPRX:
- Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)
- Ex-Dividend Date Nearing for These 10 Stocks – Week of August 14 – August 18, 2023
- Royalty Pharma raises 2023 adjusted cash reciepts guidance
- Royalty Pharma reports Q2 revenue $538M, consensus $536.59M
- Royalty Pharma Reports Second Quarter 2023 Results
